Open AccessCost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome
Author(s) -
Jan A.J.G. van den Brand,
Jacobien C. Verhave,
Eddy Adang,
Jack F.M. Wetzels
Publication year - 2017
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfw353
Subject(s) - eculizumab , medicine , atypical hemolytic uremic syndrome , transplantation , kidney transplantation , dialysis , cost effectiveness , kidney disease , kidney , surgery , immunology , complement system , antibody , risk analysis (engineering)
Kidney transplantation in patients with atypical haemolytic uraemic syndrome (aHUS) is frequently complicated by recurrence of aHUS, often resulting in graft loss. Eculizumab prophylaxis prevents recurrence, improving graft survival. An alternative treatment strategy has been proposed where eculizumab is administered upon recurrence. We combined available evidence and performed a cost-effectiveness analysis of these competing strategies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom